Big bio/pharma would rather ‘make than buy,’ says PharmSource
Leader in contract bio/pharma industry intelligence predicts ongoing in-house manufacture...
List view / Grid view
News
Bristol-Myers Squibb to present sixteen Orencia (abatacept) data abstracts at The American College of Rheumatology (ACR) 2014 annual meeting
13 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that 16 abstracts for Orencia were accepted for presentation at the 2014 annual meeting of the American College of Rheumatology (ACR) taking place from November 14-19, 2014 in Boston, MA...
Gilead announces Harvoni® (ledipasvir/sofosbuvir) study results in chronic hepatitis C patients with advanced liver disease and those who failed prior treatment
13 November 2014 | By Gilead Sciences
High cure rates in nearly 800 Hepatitis C Virus (HCV patients with advanced liver disease)...
Personalised care pushes US and European health providers to shift to the cloud
13 November 2014 | By Frost & Sullivan
Cloud service providers that offer guaranteed reliability and clear data portability terms will emerge as top contenders, finds Frost & Sullivan...
Branded generics need statutory exemption
13 November 2014 | By British Generic Manufacturers Association
Price cuts for branded generic medicines as part of proposed Government changes to the statutory scheme to control the prices of branded health service medicines will undermine innovation, create uncertainty, reduce competition and ultimately undermine patient benefits...
ABIVAX signs agreement with the Finlay Institute to commercialise meningococcal and typhoid vaccines in Asia and Latin America
13 November 2014 | By ABIVAX
ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, announced that it has signed an agreement with The Finlay Institute, Havana, Cuba...
TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule
12 November 2014 | By TiGenix NV
TiGenix NV announced that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn's patients...
Biologics to Complement Statins in Cholesterol Treatment Space, says GlobalData Analyst
12 November 2014 | By GlobalData
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData...
Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One
12 November 2014 | By Novartis
Novartis announced that, through Power of One, enough funds have been raised to deliver three million antimalarial treatments for children in Zambia...
Mundipharma calls for broader stakeholder consensus on pain trial endpoints to meet payer’s requirements
11 November 2014 | By Mundipharma
New research unveiled by Mundipharma highlights inconsistencies in health economic models and measurement methods used in clinical trials for pain therapies...
Lilly’s Trulicity™ (dulaglutide) now available in U.S. pharmacies
The newest GLP-1 receptor agonist treatment option to help improve glycemic control type 2 diabetes in adults is now available in U.S. pharmacies. Eli Lilly and Company's (LLY) Trulicity™ (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed with patients in mind. It comes in a single-dose pen…
Moberg Pharma’s nomination committee appointed
11 November 2014 | By Moberg Pharma
In accordance with the resolution of the Annual General Meeting on May 13, 2014, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee...
CPI is a key partner in H2020 consortium to develop Nanopharmaceuticals
11 November 2014 | By The Centre for Process Innovation
The Centre for Process Innovation (CPI) is part of a consortium which will focus on the development and scale up of nanopharmaceutical production...
New real-world data highlight health and financial impact of caring for an adult with schizophrenia
11 November 2014 | By Janssen
Compared with their peers and other caregivers, carers for adults with schizophrenia report deteriorated physical and mental health and greater health resource usage/utilisation...
ALLY Trial demonstrates high cure rates for investigational daclatasvir and sofosbuvir combination among genotype 3 hepatitis C patients
10 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir (DCV) in combination with sofosbuvir (SOF) in genotype 3 hepatitis C (HCV) patients, a patient population that has emerged as one of the most difficult to treat...
